ClinicalTrials.gg
CompletedNCT00358228Updated Dec 10, 2010

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)

A Phase 3 interventional study of Rimonabant in Smoking Cessation, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-10.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
787
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 920 studies in Smoking Cessation with a site in United States — 98 open to participants now, 126 under way, 7 of them phase 3. Smoking Cessation · United States.

Enrollment
135th of 872
787 · median 149
Started
2002
with 6 others
Phase 3
75 of 920
4 open now
Registered
68th of 920
by date

Among the 920 studies in Smoking Cessation with a site in United States, this one is the 135th largest by enrollment of the 872 interventional ones that give a count, is one of 7 that started in 2002, is one of 75 in phase 3, and was the 68th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

98 of the 920 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 920 studies in Smoking Cessation with a site in United States, or all of them as a file.
02

Study summary

The primary study objective was to assess the efficacy of 2 fixed doses of rimonabant versus placebo on abstinence from tobacco use in cigarette smokers.

The secondary study objectives were:

  • To evaluate the effects of rimonabant on craving and weight;
  • To evaluate the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period
  • To evaluate the population pharmacokinetics of rimonabant (ie, standard PK evaluation in the population of smokers);
  • To observe the percentage of abstinent patients during a 40-week follow-up post treatment period;
  • To evaluate quality of life (QOL) and pharmacoeconomics.
03

Conditions studied

  • Smoking Cessation

Browse trials for

Keywords

  • Smoking cessation
  • Abstinence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Smokers smoking at least 10 cigarettes/day (on average) in the 2 months preceding screening visit;
  • Motivated to quit smoking (Motivation Scale Score above or equal to 6 on a 10-point scale).

Exclusion criteria

Exclusion Criteria:

  • Smoked or consumed more than 3 times within the 3 months immediately preceding the screening visit: non tobacco cigarettes or related products or any form of tobacco product other than cigarettes;
  • Current and regular consumption of marijuana (hashish).
  • Met current criteria on the MINI International Neuropsychiatric Interview (MINI) for any of the following psychiatric disorders/states: major depressive episode, dysthymia, suicidality, manic episode or hypomanic episode, panic disorder, agoraphobia, social phobia (social anxiety disorder), obsessive compulsive disorder, posttraumatic stress disorder, alcohol dependence or abuse, substance dependence or abuse (excluding nicotine or caffeine), anorexia nervosa, bulimia nervosa, or generalized anxiety disorder;
  • Met lifetime criteria on the MINI for manic episode or hypomanic episode, or psychotic disorders;
  • Carried a diagnosis of, or suspicion of any cognitive disorder (eg, delirium, dementia, amnestic disorder) or any other psychiatric or developmental disorder as defined by the Fourth Edition (DSM-IV) that may interfere with his/her ability to understand or complete study related procedures;
  • Had a history of severe depression, ie, those who have required hospitalization, or patients with 2 or more recurrent episodes of depression, or a history of multiple suicide attempts;
  • Had used, within 3 months before the screening visit:

    • Nicotine replacement of any type for more than 3 days at the maximum prescribed dose, or
    • Behavioral and/or motivational counseling, therapy, support group, or other procedure intended to assist smoking cessation on more than 3 days, or
    • Bupropion (amphebutamone), or
    • Systemic long acting , or
    • Any therapy intended to treat or alleviate depressive symptoms (pharmacologic, somatic, or psychological) for more than 1 week.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
787 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Prolonged abstinence from tobacco smoking during the last 4 weeks of treatment (Day 43 to Day 70) as reported by direct inquiry of the patient by the Investigator, and confirmed by exhaled carbon monoxide (CO) levels, and plasma cotinine measurements.

Secondary outcomes

  1. Analysis of mean change from baseline to last evaluation of the total score of QSU.

  2. Brief scale evaluating craving for tobacco cigarettes and relative change in body weight from baseline to last evaluation in patients with BMI lower than 30 kg/m2 at baseline achieving prolonged abstinence.

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Malvern, Pennsylvania 19355, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002, a primary completion of Aug 2003 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2006
First posted
Jul 31, 2006
Start
Sep 2002
Primary completionActual
Aug 2003
CompletionActual
Aug 2003
Last update
Dec 10, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00358228
Lead sponsor
Sanofi
First posted
Jul 31, 2006
Start date
Sep 2002
Primary completion
Aug 2003
Completion
Aug 2003
Last update
Dec 10, 2010

Study contacts

Lowell C. DALE, MD
principal investigator · Mayo Clinic 200 First Street SW, Rochester, Minnesota 55905, US
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion